KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2023 - 2025)

Historic Long-Term Deferred Tax for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $126.0 million.

  • Alnylam Pharmaceuticals' Long-Term Deferred Tax rose 779.72% to $126.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $126.0 million, marking a year-over-year increase of 779.72%. This contributed to the annual value of $126.0 million for FY2025, which is 779.72% up from last year.
  • Alnylam Pharmaceuticals' Long-Term Deferred Tax amounted to $126.0 million in Q4 2025, which was up 779.72% from $98.6 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $126.0 million during Q4 2025, with a 5-year trough of $10.1 million in Q4 2023.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $105.8 million (2025), whereas its average is $93.8 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Long-Term Deferred Tax surged by 105694.49% in 2024, and later soared by 779.72% in 2025.
  • Quarter analysis of 3 years shows Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then surged by 1056.94% to $116.9 million in 2024, then increased by 7.8% to $126.0 million in 2025.
  • Its last three reported values are $126.0 million in Q4 2025, $98.6 million for Q3 2025, and $104.4 million during Q2 2025.